Literature DB >> 6226019

[Comparative elimination of pirprofen from the plasma and synovial fluid of the knee. 26 cases].

J P Schoeller, C Schwarzberg, A Gerardin, D Colussi, A Sioufi, J Hirtz.   

Abstract

Twenty-six patients with various inflammatory diseases of the knee were treated with a 400 mg dose of pirprofen orally twice a day for 2 days. On the third day, samples of blood and synovial fluid were taken 3 h and 10 h approximately after a fifth 400 mg dose of the drug. Pirprofen concentrations, as determined by gas-liquid chromatography, were higher in plasma than in synovial fluid during the 2-5 h period post-dosing. They decreased with an elimination half-life of 6 h in plasma as against 41 hours in synovial fluid. This study demonstrates that pirprofen diffuses into the synovial fluid where it remains significantly longer than in plasma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226019

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  4 in total

Review 1.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 2.  Pirprofen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; R Beresford
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

3.  Pharmacokinetics of pirprofen in children with juvenile chronic arthritis.

Authors:  F Hallé; F Marfil; A Sioufi; J P Dubois; M Gioud-Paquet; G Lenoir; A M Prieur
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

4.  Drug action on articular cartilage surface. An in vitro study using mouse femoral heads labeled with cationized ferritin.

Authors:  R Stanescu; J Peyron; V Stanescu
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.